25.27 -0.19 (-0.75%)
After hours: 6:26PM EST
|Bid||24.78 x 800|
|Ask||25.46 x 2200|
|Day's Range||24.33 - 26.28|
|52 Week Range||15.12 - 45.68|
|Beta (5Y Monthly)||N/A|
|PE Ratio (TTM)||N/A|
|Earnings Date||Mar 01, 2020|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||42.29|
Digitization of the world we live in has disrupted the healthcare industry, giving rise to the healthcare information technology (IT) segment of the market. The emergence of this space and the technology it offers has transformed the way healthcare providers and organizations care for patients. Not to mention efficiency has improved dramatically. Demand for these digital solutions isn’t expected to slow anytime soon, with Grand View Research predicting that the digital healthcare market will expand at a CAGR of 27%, reaching $509.2 billion by 2025.Bearing this in mind, investing firm J.P. Morgan took a look at several healthcare IT names ahead of their upcoming fourth quarter earnings releases.“Sentiment on the group has been largely favorable, with the group up 12% since Q3 earnings in November vs the remaining Healthcare Technology & Distribution group up 14% and the SPX 8%-plus,” analyst Anne Samuel commented.In the report, the firm highlights two tickers in particular that it believes can not only deliver solid prints, but also reward investors through 2020 and beyond. After using TipRanks’ Stock Screener tool, we found out each boasts a “Strong Buy” consensus rating from the Street, and has a substantial upside potential from the current share price. We’re talking more than 50% here.Health Catalyst Inc. (HCAT)With its cloud-based data platform, Health Catalyst offers data and analytics solutions to healthcare organizations. As the company gears up for its February 27 earnings release, J.P. Morgan has high hopes.The investment banking firm's analyst, Anne Samuel, notes that she will be focused on how many new Data Operating System (DOS) clients were added during the year as well as dollar-based retention. Additionally, Samuel highlights the fact that the company thinks the Medicity conversion opportunity is approaching an inflection point in 2020 given that this past summer, cross-sell conversations kicked off.Based on Samuel’s estimates, the analyst expects net new customers for 2019 to land at 14, which would reflect 28% year-over-year customer growth. In terms of 2020 guidance, she is forecasting 18 net new DOS subscription customers and 7% same-store growth, amounting to 25% DOS subscription revenue growth. However, thanks to Medicity drag, the total revenue gain is expected to come in at 22%. As a result, this brings the 2020 revenue prediction to $186 million, which falls in line with the consensus.While Samuel does point out that HCAT operates in a highly competitive environment and that there could be an expense shift of $200,00 from Q3 into Q4, her bullish thesis remains very much intact. “We see significant white space in an $8 billion TAM, with over 20% revenue growth driven by mid-teens annual customer wins. We estimate the company reaches EBTIDA profitability in the next four years as a maturing customer base drives incremental leverage. The model is predictable with over 90% recurring revenue, 107% net dollar-based retention, and a sticky customer base, never having lost an all-access customer,” the analyst explained.Taking all of this into consideration, Samuel maintained both her Overweight call and $50 price target. Should this target be met, shares could be in for a twelve-month gain of 66%. (To watch Samuel’s track record, click here)Overall, it has been relatively quiet when it comes to other analyst activity. In the last three months, only 3 analysts have issued ratings. However, as they were all Buys, the word on the Street is that HCAT is a Strong Buy. Based on the $48.33 average price target, shares could climb 60% higher in the next twelve months. (See Health Catalyst stock analysis on TipRanks)Livongo Health Inc. (LVGO)Moving on to the firm’s next pick, we come across Livongo Health. For patients battling chronic health conditions, its digital health platform makes it easy to access personalized digital guidance and health coaching through a smart connected device. While the healthcare name has experienced significant volatility, the firm remains optimistic.Ahead of its Q4 earnings release on March 2, Samuel, who also covers this stock, wrote that LVGO already “blessed Street numbers on its Q3 call for $276 million equating to 63% year-over-year growth.” She added, “Looking at the economic value added (EVA) that they reported in Q3, a 40% conversion rate on $208 million year-to-date EVA would equate to a 70% revenue growth run rate on our math.”When the results are announced, Samuel anticipates that the Street will be paying close attention to 2020 guidance and the sustainability of rapid growth, noting that management stated 2020 will be an “investment year”. On top of this, the analyst is hoping for an update on enrollment, pipeline for new growth and any changes in the competitive landscape.In terms of the fourth quarter figures, Samuel is calling for revenue of $49.4 million and an EBITDA loss of $5.5 million, both of which would land within the guided range. For 2020, the analyst expects the company to guide for $281 million in revenue, a 66% increase if achieved, gross profit margins of 72% and a fiscal 2020 EBITDA loss of $25 million.Despite the EBITDA figure being in the red, Samuel believes LVGO will be able to reach operating income profitability in 2021. Additionally, the analyst argued, “The company is minimally penetrated in a vast and growing chronic disease market, as more than half of the U.S. population has one or more chronic conditions and an additional 4,000 Americans are diagnosed with diabetes each day. LVGO’s rapid growth profile is attractive, and unique in Healthcare IT with our model calling for an 85% revenue CAGR over the next 3 years as the company increases its member base.”In line with her optimistic take, Samuel kept an Overweight rating and price target of $43 on the stock. This target conveys her confidence in LVGO’s ability to climb 55% higher in the next twelve months.What does the rest of the Street think about LVGO? As it turns out, other analysts are on the same page. With 100% Street support, the message is clear: the stock is a Strong Buy. Not to mention the $45.67 average price target implies 64% upside potential. (See Livongo stock analysis on TipRanks)
MOUNTAIN VIEW, Calif., Feb. 18, 2020 -- Livongo Health, Inc., (Nasdaq: LVGO), the leading Applied Health Signals company empowering people with chronic conditions to live.
Livongo Health, Inc., (LVGO) today announced it will hold a conference call on Monday, March 2, 2020, after close of the U.S. stock market at 4:30 p.m. Eastern Time to discuss results for the fourth quarter and full year 2019. For more information, visit: www.livongo.com or engage with Livongo on LinkedIn or Twitter.
Health care stocks may be under pressure from Democratic candidates' rhetoric and Congressional scrutiny, but don't dump them yet, one analyst says.
MOUNTAIN VIEW, Calif., Jan. 21, 2020 -- Livongo (Nasdaq: LVGO), a leading Applied Health Signals company empowering people with chronic conditions to live better and healthier.
Lynne Chou O'Keefe left Kleiner Perkins late in 2018 to invest in companies like Livongo Health, which she helped to take public last year. In this TechFlash Q&A;, she talks about how she plans to invest $87 million she just raised for the firm's first fund.
Livongo (LVGO), a leading Applied Health Signals company empowering people with chronic conditions to live better and healthier lives, has partnered with Dexcom, Inc. (DXCM), a leader in continuous glucose monitoring (CGM), to offer Livongo Members the ability to synch data from their Dexcom G6 Continuous Glucose Monitoring System with the Livongo platform, providing access to key insights and Health Nudges™ from Livongo’s Applied Health Signals platform based on their CGM data.
Livongo (LVGO), a leading Applied Health Signals company empowering people with chronic conditions to live better and healthier lives, and Higi, a consumer health engagement company with a nationwide network of 10,000 Smart Health Stations, today announced a partnership to create a seamless experience for people to determine their risk for chronic conditions, measure and track their health data, and enroll in Livongo’s leading chronic condition management solutions. The program will first be made available in February across nearly 500 leading pharmacy retail locations in Michigan and will scale across Higi’s full network throughout the year.
One third of this year's Bay Area companies that went public in the past 12 months entered trading on the day after Christmas below their original offering prices.
We are still in an overall bull market and many stocks that smart money investors were piling into surged through the end of November. Among them, Facebook and Microsoft ranked among the top 3 picks and these stocks gained 54% and 51% respectively. Hedge funds' top 3 stock picks returned 41.7% this year and beat […]
MOUNTAIN VIEW, Calif., Dec. 16, 2019 -- Livongo Health, Inc., (Nasdaq: LVGO), a leading Applied Health Signals company empowering people with chronic conditions to live better.
Express Scripts (CI) announced a new electronic heath formulary, potentially transforming the way digital health solutions will be paid for in the near future, with an eye toward lowering costs.
Participating health plans and employers can now expand access to Livongo’s leading Diabetes, Hypertension, and Weight Management solutionsLivongo also gains preferred status.
MOUNTAIN VIEW, Calif., Dec. 11, 2019 -- Livongo Health, Inc. (Nasdaq: LVGO) today announced the pricing of its underwritten public offering of 2,777,327 shares of its common.
Such selling stockholders also intend to grant the underwriters a 30-day option to purchase up to an additional 416,598 shares of common stock at the public offering price, less underwriting discounts and commissions. Livongo will not receive any of the proceeds from the proposed sale of the shares of its common stock being offered by the selling stockholders, and will bear the costs associated with the cost of such transaction, other than underwriting discounts and commissions. The proposed offering is subject to market and other conditions, and there can be no assurance as to whether or when the proposed offering may be completed.
MOUNTAIN VIEW, Calif., Nov. 21, 2019 -- Livongo Health, Inc., (Nasdaq: LVGO), a leading Applied Health Signals company empowering people with chronic conditions to live better.
Livongo Health, Inc. (NASDAQ: LVGO), a leading Applied Health Signals company empowering people with chronic conditions to live better and healthier lives, today announced the findings of a study that demonstrated people with both diabetes and high blood pressure who used the Livongo for Hypertension solution and the Livongo for Diabetes solution on an integrated platform saw sustained clinically-significant blood pressure reduction after only four weeks and experienced further improvements after using the program for twelve weeks. In addition, Livongo Members who checked their blood pressure more frequently using Livongo’s connected blood pressure monitoring technology experienced additional improvement for both systolic blood pressure (the top number of a blood-pressure reading) and diastolic blood pressure reduction (the bottom number of a blood-pressure reading).
Third quarter Total Revenue of $46.7 million, up 148% year-over-year207,815 enrolled Livongo for Diabetes Members, up 118% year-over-year2019 revenue guidance range raised to.
The S&P 500 closed at an all time high on Monday evening -- then closed at an even higher high on Wednesday -- 3,046.77. Goldman Sachs believes this rally could keep going well into 2020.A recent report from Goldman Sachs predicts that 2020 will see corporations spend nearly a half-trillion dollars on stock buybacks, mergers, and acquisitions next year. Add in buying by U.S. individual investors and foreign investors, and that buying could be pushed well beyond the $500 billion-mark, says Goldman Sachs analyst David Kostin, as investors seek to profit from "positive equity market returns," buoyed by "rising interest rates, and stabilizing US and World GDP growth."But where do you look to find those profits specifically?Using the Stock Screener at TipRanks to seek out highly rated stocks in the ever-growing healthcare sector, for which Goldman Sachs analysts expect to see double, near double, or more than double returns in the next 12 months, we've come up with three candidates for you today.Arvinas Holding (ARVN)Based in New Haven, Connecticut, cancer-fighter Arvinas is researching therapies to degrade cancer-causing proteins in diseases such as prostate cancer and breast cancer.Goldman Sachs analyst Terence Flynn upgraded Arvinas to "buy" with a $38 price target after reviewing the result of Phase 1 clinical trials of the company's ARV-110 (for prostate cancer) and ARV-471 (for breast cancer) drugs. (To watch Flynn's track record, click here)As the label "Phase 1" suggests, Flynn admits that "trials are still in the early stages," but initial safety data looks good, opening a path to proceed to evaluating "first clinical efficacy data." Flynn increases his probability of success for both ARV-110 and ARV-471 to 25% (vs. 20% prior) given the initial safety/PK data presented, which in his view "provide some incremental de-risking of the drugs."If all goes well, Flynn foresees "blockbuster potential" for both drugs, with potential peak sales of $2.9 billion and $4.7 billion, respectively -- a big improvement over the $15 million in revenue Arvinas has booked over the last 12 months.Street sentiment on this one is good as well, with three analysts initiating coverage of Arvinas over the last three months -- in addition to Goldman's upgrade. And like Goldman, all three of these other analysts rate the stock a "buy," which qualifies the stock for "strong buy" sentiment in our book. A consensus target price of $38 (in line with Goldman's own target price) implies 81% upside for the shares over the next 12 months. (See Arvinas stock analysis on TipRanks)Livongo Health (LVGO)Next up: taking a different path to healthcare, Livongo Health is a Mountain View, California, software company seeking to harness data to improve patient outcomes in the fields of hypertension treatment, diabetes care, and weight management.This one attracted the attention of Goldman Sachs analyst Robert Jones, after Livongo was awarded a contract "to provide the Livongo for Diabetes solution to eligible members covered by the Federal Employees Health Benefits program under one health plan covering 5.3mn lives." Beginning on January 1, 2020, and for at least nine to 12 months thereafter, Livongo will work to reduce diabetes in the federal workforce -- and receive between $20 million and $25 million for its services in 2020, and perhaps $30 million to $35 million in 2021 if all goes well.This single contract, therefore, holds the potential to grow Livongo's $113 million in trailing revenues by 22% next year -- and push Livongo stock up as high as $43 a share, in Jones' estimation, over the next 12 months.The rest of Wall Street is even more optimistic. More than half a dozen analysts have chimed in over the past couple of months, most with buy ratings, and with an average price target of $43.63. If they're right, that means Livongo stock could more than double over the next 12 months. (See Livongo stock analysis on TipRanks)Myovant Sciences (MYOV) Returning to the pharmaceutical field now, but shifting our gaze to the UK, London-based Myovant Sciences is a clinical-stage biopharmaceutical company working to develop drugs for use in women's health, with backing from Japan's Sumitomo Dainippon Pharma, which took a 46% stake in the company last quarter and is helping to move Myovant towards commercial production.Goldman Sachs analyst Paul Choi isn't looking for earnings to be much of a catalyst for the stock (because there are none). But sales revenue is anticipated to begin rolling in next year, and could quadruple to more than $153 million by 2021. Furthermore, Choi recommends the stock in anticipation of the companies signing a "definitive agreement" of their partnership, assigning Myovant stock a "buy" rating and an $18 price target. (To watch Choi's track record, click here)Wall Street as a whole is similarly bullish, with three "buy" ratings filed in the last two months (including Goldman's), making the stock a "Strong Buy" according to TipRanks. With Street analysts positing an average $22 average price target, Myovant shows the most profit potential of all on today's list -- 325% to be exact. (See Myovant stock analysis on TipRanks)
MOUNTAIN VIEW, Calif., Oct. 31, 2019 -- Livongo Health, Inc., (Nasdaq: LVGO), a leading Applied Health Signals company empowering people with chronic conditions to live better.
Livongo Health, Inc. (Nasdaq: LVGO), a leading Applied Health Signals company empowering people with chronic conditions to live better and healthier lives, today announced at the HLTH 2019 Conference being held in Las Vegas, Nevada, that it has teamed with MDLIVE and Doctor On Demand to enable access to virtual acute and primary care services for people living with chronic conditions. Livongo will enable access to telehealth services for Livongo Members, beginning with Livongo for Behavioral Health, effective January 2020, and soon expanding to Livongo’s diabetes and hypertension offerings.
Livongo Health, Inc. (Nasdaq: LVGO), a leading Applied Health Signals company empowering people with chronic conditions to live better and healthier lives, today announced that it has expanded its partnership with Blue Cross and Blue Shield of Kansas City (Blue KC) to offer the Livongo for Diabetes program to all Blue KC fully insured clients. In addition, Livongo is now available to eligible Blue KC Administrative Services Only (ASO) clients. To date, Blue KC clients using Livongo demonstrated a combined +75 NPS score and a significant decrease in eHbA1c.
Yahoo Finance’s Anjalee Khemlani sits down with Livongo CEO Zane Burke at the J.P. Morgan Annual Health Care Conference and gets his thoughts on innovation in health care, outlook, and much more.